Clonal evolution in cancer. Nature

Division of Molecular Pathology, The Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Nature (Impact Factor: 41.46). 01/2012; 481(7381):306-13. DOI: 10.1038/nature10762
Source: PubMed


Cancers evolve by a reiterative process of clonal expansion, genetic diversification and clonal selection within the adaptive landscapes of tissue ecosystems. The dynamics are complex, with highly variable patterns of genetic diversity and resulting clonal architecture. Therapeutic intervention may destroy cancer clones and erode their habitats, but it can also inadvertently provide a potent selective pressure for the expansion of resistant variants. The inherently Darwinian character of cancer is the primary reason for this therapeutic failure, but it may also hold the key to more effective control.

Download full-text


Available from: Carlo Maley, Mar 24, 2015
  • Source
    • "In evolutionary context, therapy can be considered as a selective pressure differentially acting on the myeloma clones and impacting on their chances of survival. In this context, the critical mechanism for tumor progression is the competition between individual clones for the same microenvironmental 'niche' and the avoidance of selective pressures exerted by the immune system, combined with the process of adaptation and natural selection (Greaves and Maley, 2012). Once treatment has been initiated, the selective pressures change and possibly the evolution of the tumor is enhanced by exposure to treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is composed of an array of multiple clones, each potentially associated with different clinical behavior. Previous studies focused on clinical implication of centrosome amplification (CA) in MM show contradictory results. It seems that the role of CA as well as CA formation in MM differ from other malignancies. This has brought about a question about the role of CA positive clone which is-is it going to be a more aggressive clone evolutionally arising under pressure of negative conditions or can CA serve as a marker of cell abnormality and lead to cell death and further elimination of this damaged subpopulation? This current review is devoted to the discussion of the existence of MM subclones with centrosome amplification (CA), its evolutionary behaviour within intraclonal heterogeneity as well as its potential impact on the disease progression and MM treatment.
    Critical reviews in oncology/hematology 11/2015; DOI:10.1016/j.critrevonc.2015.10.019 · 4.03 Impact Factor
    • "Cancers develop through a process of clonal evolution in which ongoing genetic and epigenetic diversification allows for repeated cycles of subclonal selection and expansion (Greaves and Maley, 2012; Nowell, 1976). As a result, human tumors can display substantial intratumoral heterogeneity, including discordant genetic alterations between initial tumors and their associated local recurrences or distant metastases (Gerlinger et al., 2012; Okosun et al., 2014; Wu et al., 2012; Yachida et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The evolutionary history of tumor cell populations can be reconstructed from patterns of genetic alterations. In contrast to stable genetic events, epigenetic states are reversible and sensitive to the microenvironment, prompting the question whether epigenetic information can similarly be used to discover tumor phylogeny. We examined the spatial and temporal dynamics of DNA methylation in a cohort of low-grade gliomas and their patient-matched recurrences. Genes transcriptionally upregulated through promoter hypomethylation during malignant progression to high-grade glioblastoma were enriched in cell cycle function, evolving in parallel with genetic alterations that deregulate the G1/S cell cycle checkpoint. Moreover, phyloepigenetic relationships robustly recapitulated phylogenetic patterns inferred from somatic mutations. These findings highlight widespread co-dependency of genetic and epigenetic events throughout brain tumor evolution.
    Cancer cell 09/2015; 28(3):307-17. DOI:10.1016/j.ccell.2015.07.012 · 23.52 Impact Factor
  • Source
    • "The unique ability to detect differing transcriptional profiles in sub-clones might be relevant to tracking changes in the tumor clonal architecture, as sub-clonal dominance are known to change due to the influence of selection pressures during tumor evolution/oncogenesis and, more importantly, during the course of treatment (Greaves and Maley, 2012). Such shifts in clonal dominance are accompanied by subsequent changes in the molecular anatomy of the dynamically adapting tumor, particularly its proliferating subset driving tumor growth. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intratumor heterogeneity is a primary feature of high-grade gliomas, complicating their therapy. As accumulating evidence suggests that intratumor heterogeneity is a consequence of cellular subsets with different cycling frequencies, we developed a method for transcriptional profiling of gliomas, using a novel technique to dissect the tumors into two fundamental cellular subsets, namely, the proliferating and non-proliferating cell fractions. The tumor fractions were sorted whilst maintaining their molecular integrity, by incorporating the thymidine analog 5-ethynyl-2′-deoxyuridine into actively dividing cells. We sorted the actively dividing versus non-dividing cells from cultured glioma cells, and parental and clonally derived orthotopic tumors, and analyzed them for a number of transcripts. While there was no significant difference in the transcriptional profiles between the two cellular subsets in cultured glioma cells, we demonstrate ∼2–6 fold increase in transcripts of cancer and neuronal stem cell and tumor cell migration/invasion markers, and ∼2-fold decrease in transcripts of markers of hypoxia and their target genes, in the dividing tumor cells of the orthotopic glioma when compared to their non-proliferative counterparts. This suggests the influence of the brain microenvironment in transcriptional regulation and, thereby, the physiology of glioma cells in vivo. When clonal glioma cells were derived from a parental glioma and the resultant orthotopic tumors were compared, their transcriptional profiles were closely correlated to tumor aggression and consequently, survival of the experimental animals. This study demonstrates the resolution of intratumor heterogeneity for profiling studies based on cell proliferation, a defining feature of cancers, with implications for treatment design.
    Molecular oncology 09/2015; DOI:10.1016/j.molonc.2015.09.001 · 5.33 Impact Factor
Show more